Analysts’ Recent Ratings Updates for Puma Biotechnology (PBYI)

A number of research firms have changed their ratings and price targets for Puma Biotechnology (NYSE: PBYI):

  • 10/9/2017 – Puma Biotechnology had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $135.00 price target on the stock, up previously from $117.00.
  • 10/5/2017 – Puma Biotechnology had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $156.00 price target on the stock, up previously from $114.00.
  • 10/4/2017 – Puma Biotechnology had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $131.00 price target on the stock.
  • 10/3/2017 – Puma Biotechnology was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 10/2/2017 – Puma Biotechnology had its price target raised by analysts at Stifel Nicolaus from $110.00 to $130.00. They now have a “buy” rating on the stock.
  • 9/27/2017 – Puma Biotechnology had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $136.00 price target on the stock.
  • 9/11/2017 – Puma Biotechnology had its price target raised by analysts at Credit Suisse Group from $118.00 to $136.00. They now have an “outperform” rating on the stock.
  • 9/8/2017 – Puma Biotechnology was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 9/6/2017 – Puma Biotechnology is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $103.00 price target on the stock.

Shares of Puma Biotechnology Inc (NYSE:PBYI) traded up 0.40% on Tuesday, hitting $124.65. 148,837 shares of the stock traded hands. The stock’s market cap is $4.64 billion. The stock has a 50-day moving average price of $108.65 and a 200 day moving average price of $77.41. Puma Biotechnology Inc has a 12-month low of $28.35 and a 12-month high of $127.02.

Puma Biotechnology (NYSE:PBYI) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.78). On average, analysts anticipate that Puma Biotechnology Inc will post ($8.69) earnings per share for the current fiscal year.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 13,175 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $94.73, for a total value of $1,248,067.75. Following the completion of the transaction, the insider now directly owns 4,170,623 shares in the company, valued at $395,083,116.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $120.00, for a total value of $1,800,000.00. Following the completion of the transaction, the senior vice president now owns 42,239 shares of the company’s stock, valued at $5,068,680. The disclosure for this sale can be found here. Insiders sold 45,173 shares of company stock valued at $4,738,189 over the last quarter. Corporate insiders own 22.70% of the company’s stock.

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.